IL5 and chronic rhinosinusitis: For example, mepolizumab, a humanized, anti-interleukin-5 monoclonal antibody, has been approved for the treatment of patients with severe asthma, hypereosinophilic syndrome, EGPA, and chronic rhinosinusitis with nasal polyps [39].